US FDA inspection at Aurobindo subsidiary Unit-IV ends with zero observations

Regulatory & Legal View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹1679.80

prior close

₹1688.00

announcement price

After-mkt

timing

Nifty Midcap 150market-2.1%+1.0% vs market

Pharmaceuticals peers, median of 172sector-1.9%+0.7% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Midcap 150 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.0

15m

-0.7

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-2.1+1.0-1.9+0.7

Next day

-1.6-2.1+0.5-2.1+0.5

+0.2-1.2+1.4-1.2+1.4

+0.9+0.2+0.7-0.4+1.3

+2.3-0.1+2.4+0.2+2.0

+1.1-0.3+1.3-0.1+1.1

+2.4-1.7+4.0-0.2+2.6

15d

+0.1-4.4+4.6-3.1+3.2

-0.1-4.8+4.7-6.0+5.9

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA inspected Unit-IV API facility of Apitoria Pharma, a wholly owned subsidiary of Aurobindo Pharma, located at Pydibhimavaram, Andhra Pradesh, from Sept 7 to Sept 11, 2026. The inspection concluded with zero observations, meaning no compliance issues were flagged. This supports uninterrupted API supply for US markets and reflects positively on manufacturing quality standards.

Likely market impact

Positive for shareholders. Clean FDA outcome with zero observations supports uninterrupted US supply and validates quality standards at the API facility.